If there are significant real revenue contract, you will be buying at 30c+ on open but I read this announcement as there will be European countries and telehealth that will look at the CE approval....possibly a "sign" that the FDA didn't decline the De Novo application on safety and efficacy as those double blind clinical trial results were very good.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Builds European Market Presence
Ann: ResApp Builds European Market Presence, page-74
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 190 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)